Immunological synapse formation as a key mechanism in T cell-dependent bispecific antibody-mediated immune activation and cytotoxicity
Cancer Immunology, Immunotherapy · 2025
DOI: 10.1007/s00262-025-04036-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Rikuto Nakamura und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Developmental Therapeutics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Chiba, 277-8577, Japan. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Immunological Synapses, T-Lymphocytes, Lymphocyte Activation. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Cancer Center Research and Development Fund, AMED.
Abstract (Originalsprache)
T cell-dependent bispecific antibodies (TDBs) are next-generation antibody therapies that link cancer cells and T cells to achieve potent antitumor effects. Despite the successful development of TDBs for hematological malignancies, their efficacy against solid tumors remains limited. Overcoming this challenge requires a deeper understanding of their mechanisms of action. While the basic process of immunological synapse (IS) formation and T cell activation by TDB is known, the detailed effects of IS on the bystander effect and T cell migration, both crucial for therapeutic efficacy, remain unclear. This study investigated these mechanisms using an EGFR/CD3 TDB (hEx3) and EGFR knockout cancer cells (KO). The results revealed that IS formation by TDB induced a bystander effect, leading to damage in surrounding KO, with the extent depending on the proportion of EGFR-positive wild-type cancer cells (WT) and the duration of co-culture. Furthermore, IS formation significantly enhanced T cell cytokine and chemokine secretion, promoting T cell migration. These findings provide critical insights into TDB efficacy mechanisms and highlight the importance of evaluating IS formation in developing new antibody drugs. Establishing a reliable system for assessing IS formation will be essential for advancing TDBs and other antibody-based therapies, particularly against solid tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Developmental Therapeutics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Chiba, 277-8577, Japan.
- Department of Integrated Biosciences, Graduate School of Frontier Sciences, The University of Tokyo, Chiba, 277-8562, Japan.
- Department of Chemistry and Materials Science, National Institute of Technology (KOSEN), Gunma College, Gunma, 371-0845, Japan.
- Department of Biotechnology and Life Science, Graduate School of Engineering, Tokyo University of Agriculture and Technology, Tokyo, 184-8588, Japan.
- Division of Developmental Therapeutics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Chiba, 277-8577, Japan. mayasuna@east.ncc.go.jp.
Förderung
- National Cancer Center Research and Development Fund
- AMED
Zitieren
APA
Nakamura, R., Tsumura, R., Anzai, T., Asano, R., & Yasunaga, M. (2025). Immunological synapse formation as a key mechanism in T cell-dependent bispecific antibody-mediated immune activation and cytotoxicity. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04036-w
Vancouver
Nakamura R, Tsumura R, Anzai T, Asano R, Yasunaga M. Immunological synapse formation as a key mechanism in T cell-dependent bispecific antibody-mediated immune activation and cytotoxicity. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04036-w
BibTeX
@article{Nakamura2025,
author = {Nakamura, Rikuto and Tsumura, Ryo and Anzai, Takahiro and Asano, Ryutaro and Yasunaga, Masahiro},
title = {Immunological synapse formation as a key mechanism in T cell-dependent bispecific antibody-mediated immune activation and cytotoxicity},
journal = {Cancer Immunology, Immunotherapy},
year = {2025},
doi = {10.1007/s00262-025-04036-w}
}
EUVIMED